RA Capital Management 13F holdings, Q2 2008
Holdings as of June 30, 2008 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 22 US equity positions worth $219.9m in its Q2 2008 13F filing. The largest position was SEQUENOM INC at 42.6% of the reported book, followed by ONYX PHARMACEUTICALS INC and PHARMASSET INC. Against the Q1 2008 filing, it opened 9 new positions, added to 4 and reduced 8 among the top 22 holdings.
What did RA Capital Management own in Q2 2008? Top 22 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2008 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 42.6% | $93.7m | 5,872,966 | – | new | |
| 2 | ONYX PHARMACEUTICALS INC | 7.4% | $16.2m | 456,159 | -20% | reduced | |
| 3 | PHARMASSET INC | 6.7% | $14.7m | 781,071 | – | new | |
| 4 | QUESTCOR PHARMACEUTICALS INC | 6.1% | $13.3m | 2,870,428 | 9% | added | |
| 5 | ROCKWELL MEDICAL TECH | 4.4% | $9.6m | 1,370,667 | 0% | held | |
| 6 | JAVELIN PHARMACEUTICALS INC | 4.3% | $9.4m | 4,056,740 | 117% | added | |
| 7 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 3.9% | $8.6m | 255,644 | -64% | reduced |
| 8 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 3.9% | $8.6m | 2,040,838 | -16% | reduced |
| 9 | CRIS CURIS INC | 3.8% | $8.4m | 5,750,564 | -24% | reduced | |
| 10 | AMAG AMAG PHARMACEUTICALS INC | 3.4% | $7.4m | 216,780 | – | new | |
| 11 | ARDEA BIOSCIENCES INC | 2.6% | $5.7m | 441,987 | 46% | added | |
| 12 | MIDDLEBROOK PHARMACEUTICAL I | 2.5% | $5.4m | 1,604,167 | -50% | reduced | |
| 13 | OREXIGEN THERAPEUTICS INC | 1.8% | $4.0m | 507,864 | 66% | added | |
| 14 | ALLOS THERAPEUTICS INC | 1.6% | $3.5m | 500,000 | – | new | |
| 15 | ATHERSYS INC | 1.4% | $3.1m | 1,274,662 | -2% | reduced | |
| 16 | COUGAR BIOTECHNOLOGY INC | 1.1% | $2.5m | 103,498 | -49% | reduced | |
| 17 | GENELABS TECHNOLOGIES INC | 0.7% | $1.6m | 2,520,153 | – | new | |
| 18 | SOMAXON PHARMACEUTICALS INC | 0.6% | $1.4m | 293,012 | – | new | |
| 19 | LIPID SCIENCES INC ARIZ | 0.6% | $1.2m | 2,962,962 | -17% | reduced | |
| 20 | ALEXZA PHARMACEUTICALS INC | 0.4% | $879.0k | 223,143 | – | new | |
| 21 | HANA BIOSCIENCES INC | 0.2% | $360.0k | 500,000 | – | new | |
| 22 | DYNAVAX TECHNOLOGIES CORP | 0.2% | $355.0k | 242,983 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.